{
	"kj8twevsText": "Brinte<span class=\"_ _1\"></span>llix® is<span class=\"_ _1\"></span> superior t<span class=\"_ _1\"></span>o Agomelat<span class=\"_ _1\"></span>ine in<span class=\"_ _1\"></span> t<span class=\"_ _1\"></span>reating<span class=\"_ _1\"></span> <br><span class=\"ls11 ws2b\">par<span class=\"_ _1\"></span>t<span class=\"_ _1\"></span>ial responder<span class=\"_ _1\"></span>s to<span class=\"_ _1\"></span> previ<span class=\"_ _0\"></span>ous<span class=\"_ _1\"></span> antidepres<span class=\"_ _1\"></span>sant<span class=\"fs2 ls0 v1\">1</span></span>",
	"kj8twevtText": "Study Design",
	"kj8twew2Text": "Efficacy without ",
	"kj8twew3Text": "compromising ",
	"kj8twew4Text": "tolerability<span class=\"fs1d v4\">†</span>",
	"kj8twew5Text": "Remission",
	"kj8twew6Text": "rate",
	"kj8twew7Text": "Switching",
	"kj8twew8Text": "Strategies",
	"kj8twewaText": "Sub-optimal responses",
	"kj8twewbText": "to SSRI/SNRI",
	"Brintellix_48d1df5cde": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 20px;\">\n\tChange in MADRS total score from baseline<sup>1</sup>\n</font>\n</span>",
	"Brintellix_483839d0e8": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 16px;\">\n\tTreatment week\n</font>\n</span>",
	"Brintellix_48d1e36933": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 16px;\">\n\tMean change from baseline\n</font>\n</span>",
	"Brintellix_488e7c284d": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\"><div style=\"text-align: center;\"><span style=\"font-size: 15px;\">Primary</span></div>\n<font style=\"font-size: 15px;\"><div style=\"text-align: center;\">endpoint</div></font></span>",
	"Brintellix_48d17dba00": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\"><div style=\"text-align: center;\"><span style=\"font-size: 15px;\">LOCF</span></div>\n<font style=\"font-size: 15px;\"><div style=\"text-align: center;\">endpoint</div></font></span>",
	"Brintellix_48c715f4fc": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 13.5px;\">\n\t<font style=\"font-size: 30px;display:inline-block;vertical-align:middle;\">•</font> Agomelatine 25 mg–50 mg (n=241) (active comparator)\n</font>\n</span>",
	"Brintellix_487c44353b": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(84, 122, 129); display: block;\">\n<font style=\"font-size: 13.5px;\">\n\t<font style=\"font-size: 30px;display:inline-block;vertical-align:middle;\">•</font> Brintellix<sup>®</sup> 10 mg – 20 mg (n=252)\n</font>\n</span>",
	"Brintellix_48a5e63a41": "<p style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; color: rgb(100, 94, 94); line-height: 1;display:block;\">\n<font style=\"font-size: 11.5px;\">\n\t*As measured by MADRS; FAS, MMRM by visit and LOCF (FAS, ANCOVA) at Week 8. <br>\n\t**p&lt;0.01; ***p&lt;0.001 vs. agomelatine. <br>\n\tFrom REVIVE: a multicentre, randomised, double-blind study to compare the efficacy and safety of Brintellix<sup>®</sup> vs. agomelatine in <br>\n\tadult patients who had responded suboptimally† to SSRI or SNRI‡ treatment. Patients were treated with Brintellix<sup>®</sup> 10 mg – 20 mg <br>\n\tor agomelatine 25 mg – 50 mg daily. The primary endpoint was change in MADRS total score at Week 8 (FAS, MMRM) relative to <br>\n\tagomelatine. <br>\n\t<sup>†</sup>Patients included in this study had an average MADRS score of 29.1 and item score (apparent sadness) of ≥3 at screening and baseline, <br>\n\tand were non or partially responsive to a single treatment course of SSRI or SNRI for ≥6 weeks. ‡SSRI – citalopram, escitalopram, <br>\n\tparoxetine, sertraline; SNRI – duloxetine or venlafaxine. <br>\n\t<sup>§</sup>Brintellix<sup>®</sup> does not exhibit many of the side effects typical of SSRIs and SNRIs including sexual dysfunction and weight gain.<sup>4-7</sup> Side <br>\n\teffects associated with Brintellix<sup>®</sup> were compared with those of the SSRIs escitalopram and paroxetine and with those of the SNRI <br>\n\tvenlafaxine. For the 20 mg/day dose, an increase in treatment-emergent sexual dysfunction was seen compared to placebo. Please refer <br>\n\tto the full Summary of Product Characteristics or Prescribing Information for further information on safety and tolerability. <br>\n\tFAS, full analysis set; LOCF, last observation carried forward; MADRS, Montgomery-Åsberg Depression Rating Scale; MMRM, mixed <br>\n\tmodel for repeated measures.\n</font>\n</p>",
	"Brintellix_481e1bf14f": "<span style=\"font-family: &quot;3_CCMVBT+AvenirNextLTPro-Demi&quot;; color: #fff;\">\n\t<div style=\"text-align: center;\"><span style=\"font-size: 13.5px;\">STAR*D</span></div>\n</span>",
	"Brintellix_4833f10dfb": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 22.5px;\">\n\tMore than half of patients with suboptimal response achieve remission\nafter switching to Brintellix<sup>®1</sup>\n</font>\n</span>",
	"Brintellix_4862549dd1": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 16px;\">\n\tREVIVE - MADRS Remission Rate (FAS, LOCF)<sup>1</sup>\n</font>\n</span>",
	"Brintellix_483f625587": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 16px;\">\n\tSTAR*D - QIDS-SR<sub>16</sub> remission rate<sup>2</sup>\n</font>\n</span>",
	"Brintellix_48e20de956": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 14px;\">\n\tRemission Rate (%)\n</font>\n</span>",
	"Brintellix_487694b61e": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 14px;\">\n\tRemission Rate (%)\n</font>\n</span>",
	"Brintellix_48c1865c11": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(84, 122, 129); display: block;\">\n<font style=\"font-size: 13.5px;\">\n\tBrintellix<sup>®</sup> 10-20 mg (n=252)\n</font>\n</span>",
	"Brintellix_48dfee5a9f": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 13.5px;\">\n\tAgomelatine 25-50 mg (n=241) (active comparator)\n</font>\n</span>",
	"Brintellix_48205b9a5d": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 11.5px;\">\n\t** p&lt;0.01, *** p&lt;0.001 vs agomelatine; in REVIVE, remission was defined as MADRS total score ≤10; note that results shown are at different time-points, and <br>\n\tderived from two studies (STAR*D and REVIVE) and different designs and definitions of remission; FAS = full analysis set; LOCF = last observation carried <br>\n\tforward; MADRS = Montgomery-Asberg Depression Rating Scale; QIDS-SR<sub>16</sub>=16-ltem Quick Inventory of Depressive Symptomatology, self-report. <br>\n\t<b>1.</b> Montgomery SA et al. Hum Psychopharmacol Clin Exp 2014;29:470-482. <b>2.</b> Rush AJ et al. Am J Psychiatry 2006;163:1905-1917.\n</font>\n</span>",
	"Brintellix_484618b2be": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: #f28700; \">\n<font style=\"font-size: 15px;\">Zoom</font>\n</span>",
	"Brintellix_48c7f932ff": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: #f28700; \">\n<font style=\"font-size: 15px;\">Zoom</font>\n</span>",
	"Brintellix_48002584c2": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 22.5px;\">\n\tREVIVE - MADRS Remission Rate (FAS, LOCF)<sup>1</sup>\n</font>\n</span>",
	"Brintellix_4869c1a857": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 17.5px;\">\n\tRemission Rate (%)\n</font>\n</span>",
	"Brintellix_48c841e536": "<span style=\"font-family: &quot;3_CCMVBT+AvenirNextLTPro-Demi&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 17.5px;\">\n\tWeek 8\n</font>\n</span>",
	"Brintellix_4870b2e429": "<span style=\"font-family: &quot;3_CCMVBT+AvenirNextLTPro-Demi&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 17.5px;\">\n\tWeek 12\n</font>\n</span>",
	"Brintellix_48534cc9a6": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 15px;\">\n\tAgomelatine 25-50 mg (n=241) (active comparator)\n</font>\n</span>",
	"Brintellix_48be821080": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 22.5px;\">\n\tSTAR*D - QIDS-SR<sub>16</sub> remission rate<sup>2</sup>\n</font>\n</span>",
	"Brintellix_48d111466e": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 17.5px;\">\n\tRemission Rate (%)\n</font>\n</span>",
	"Brintellix_4821dce17e": "<span style=\"font-family: &quot;3_CCMVBT+AvenirNextLTPro-Demi&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 17.5px;\">\n\tStep 1\n</font>\n</span>",
	"Brintellix_486e7776f7": "<span style=\"font-family: &quot;3_CCMVBT+AvenirNextLTPro-Demi&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\">\n<font style=\"font-size: 17.5px;\">\n\tStep 2\n</font>\n</span>",
	"Brintellix_4850271d24": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\"><font style=\"font-size: 22.5px;\">Switching strategies<sup>1</sup>\n</font>\n</span>",
	"Brintellix_4880e3c02f": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\"><div style=\"text-align: center;\"><span style=\"font-size: 16px;\">Approximate occupancy&nbsp;</span></div><font style=\"font-size: 16px;\"><div style=\"text-align: center;\">of the 5-HT transporter (%)</div></font></span>",
	"Brintellix_4818773504": "<span style=\"font-family: &quot;1_CWOXIJ+AvenirNextLTPro-Bold&quot;; color: rgb(84, 122, 129); line-height: 1;display:block;\"><div style=\"text-align: center;\"><span style=\"font-size: 16px;\">Days</span></div></span>",
	"Brintellix_48cbc2d2de": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(84, 122, 129); display: block;\">\n<font style=\"font-size: 15px;\">\n\tConsider a crossover for at<br>\n\tleast 2 weeks when switching<br>\n\tto Brintellix<sup>®</sup> (Vortioxetine)\n</font>\n</span>",
	"Brintellix_48558081e3": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(84, 122, 129); display: block;\">\n<font style=\"font-size: 15px;\">\n\tPossibility of<br>\ndiscontinuation<br>\nproblems\n</font>\n</span>",
	"Brintellix_48c82174f3": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 15px;\">\n\tVenlafaxine\n</font>\n</span>",
	"Brintellix_485f3ff207": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 15px;\">\n\tEscitalopram\n</font>\n</span>",
	"Brintellix_48c014dbfd": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 15px;\">\n\tVortioxetine\n</font>\n</span>",
	"Brintellix_486f3e75d8": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 15px;\">\n\tFluoxetine\n</font>\n</span>",
	"Brintellix_483d2b7d06": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 11.5px;\">\n\tAs illustrated above, SSRIs or SNRIs are eliminated within several days, thereby rapidly decreasing the occupancy of the 5-HT transporters, but vortioxetine steady-state plasma concentrations are achieved only after 2 weeks. Consequently, discontinuation symptoms might occur during a rapid switch. Therefore, implementation of a gradual crossover strategy is recommended when switching a patient from SSRIs or SNRIs to vortioxetine. One exception would be a switch from fluoxetine, because of its long half-life. However, because fluoxetine is a CYP2D6 inhibitor, the initial dosage of vortioxetine should be 5 mg/day, and the dosage should be gradually increased as fluoxetine is slowly eliminated.\n\t<span style=\"display: inline-block;padding-top: 10px;\"><b>1.</b> American Psychiatric Association Publishing Textbook of Psychopharmacology. Fifth Edition. Chapter 16. Vortioxetine</span>\n<br>\n</font>\n</span>",
	"Brintellix_48da236cb5": "<span style=\"font-family: &quot;3_CCMVBT+AvenirNextLTPro-Demi&quot;; color: rgb(84, 122, 129); \">\n<font style=\"font-size: 25px;\">References</font>\n</span>",
	"Brintellix_48d68aaec9": "<span style=\"font-family: &quot;2_PIDSIJ+AvenirNextLTPro-Regular&quot;; line-height: 1; color: rgb(100, 94, 94); display: block;\">\n<font style=\"font-size: 15px;\">\n\t<b>1.</b> Montgomery SA et al. Hum Psychopharmacol Clin Exp 2014;29:470-482.\n<br>\n</font>\n</span>",
	"Brintellix_48cb820ef7": "Text",
	"Brintellix_48f8eecaff": "Text",
	"Brintellix_487ff19215": "Text",
	"Brintellix_486952ae0a": "Text",
	"Brintellix_489e8d6ceb": "Text",
	"Brintellix_489ba103a0": "Text",
	"Brintellix_4862e80800": "Text",
	"Brintellix_485224c8bc": "Text",
	"Brintellix_48d7b7ce2c": "Text",
	"Brintellix_48f969b326": "Text",
	"Brintellix_481c01fa5d": "Text",
	"Brintellix_48be97e30f": "<div style=\"font-family: serif;font-family: '2_VDWFON+AvenirNextLTPro-Demi';font-size: 13px;background-color: #e5f0f2;box-sizing: border-box;color: #4d7f86;\">\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">MADRS 10</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Physical symptoms</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Remission</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Relapse prevention</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Short term</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Long term</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Meta-analysis</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 4px 12px 3px;line-height:1.3;background-color: #e5f0f2;color: #fff;background: rgb(233,90,0);background: linear-gradient(90deg, rgba(233,90,0,1) 0%, rgba(240,125,0,1) 100%);background: -webkit-linear-gradient(90deg, rgba(233,90,0,1) 0%, rgba(240,125,0,1) 100%);\">Suboptimal responses<br>to SSRI/SNRI</div>\n</div>",
	"Brintellix_48c77d3c45": "Text"
}
